Publications
RSC Pharmaceutics, 2026.
We developed advanced lipopolymer nanoparticles (LPNPs) utilizing our proprietary delivery platform for targeted silencing of the upstream inflammatory sensor NLRP3 with siRNA. In vitro evaluations confirmed that optimized LPNPs achieve robust sequence-specific transcript knockdown and effectively suppress lipopolysaccharide (LPS)-induced interleukin-1 beta production in both murine macrophages and human peripheral blood mononuclear cells (PBMCs). Systemic intravenous administration in an in vivo murine endotoxemia model significantly attenuated interleukin-1 beta secretion, with particularly pronounced reductions in immune-dense tissues such as the lungs and spleen. Ex vivo translational validation using primary blood samples demonstrated consistent and marked cytokine reduction across a majority of the cohort.
Advanced Healthcare Materials, 2025;14(27):e02019.
This study highlights of our proprietary delivery platform, Comprehensive preclinical safety assessments following repeated intravenous dosing confirmed excellent systemic biocompatibility, with normal hematological profiles and no significant alterations in key organ biomarkers.
ACS Pharmacology and Translational Science, 2024;7(9):2840–2855.
The LPNP formulation demonstrated Comprehensive ex vivo immunogenicity assays demonstrated that our LPNPs possess an outstanding safety profile, failing to trigger unwanted immune responses or stimulate the secretion of key proinflammatory cytokines such as IL-6, TNF-α, and IFN-γ in human PBMCs.
Molecular Pharmaceutics, 2024;21(3):1436–1449.
This foundational pharmacokinetic study evaluated the in vivo biodistribution and systemic delivery efficiency of our proprietary delivery platform across preclinical models. Using sensitive stem-loop RT-PCR and digital droplet PCR workflows, we tracked the systemic fate of intravascularly administered small interfering RNAs. The delivery platform successfully overcame pharmacokinetic barriers, exhibiting robust extrahepatic accumulation and preferential distribution into key therapeutic targets including the lungs, spleen, and bone marrow. Comparative pharmacokinetic profiling demonstrated superior tissue deposition and prolonged systemic retention relative to conventional lipid nanoparticle (LNP) formulations.